001032446 001__ 1032446
001032446 005__ 20250203133219.0
001032446 0247_ $$2doi$$a10.1093/neuonc/noae192
001032446 0247_ $$2ISSN$$a1522-8517
001032446 0247_ $$2ISSN$$a1523-5866
001032446 0247_ $$2pmid$$a39351771
001032446 0247_ $$2WOS$$aWOS:001374738400004
001032446 037__ $$aFZJ-2024-06252
001032446 082__ $$a610
001032446 1001_ $$00000-0002-9408-3278$$aLe Rhun, Emilie$$b0$$eCorresponding author
001032446 245__ $$aTargeted radionuclide therapy for patients with CNS metastasis: overlooked potential?
001032446 260__ $$aOxford$$bOxford Univ. Press$$c2024
001032446 3367_ $$2DRIVER$$aarticle
001032446 3367_ $$2DataCite$$aOutput Types/Journal article
001032446 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1737442202_21955
001032446 3367_ $$2BibTeX$$aARTICLE
001032446 3367_ $$2ORCID$$aJOURNAL_ARTICLE
001032446 3367_ $$00$$2EndNote$$aJournal Article
001032446 520__ $$aTargeted radionuclide therapy is an emerging therapeutic concept for metastatic cancer that can be considered if a tumor can be delineated by nuclear medicine imaging and also targeted based on expression of a particular target (thera-nostics). This mode of treatment can also compete with or supplement conventional radiotherapy e.g., if MRI does not fully capture the extent of disease, including microscopic metastases. Targeted radionuclide therapy for patients with thyroid cancer, with certain somatostatin receptor 2-expressing tumors and with prostate-specific membrane antigen (PSMA)-expressing prostate cancer are approved, and numerous approaches of targeted radionuclide therapy for patients with metastatic cancer are in development (e.g. using fibroblast activation protein (FAP) as a target). Although brain metastases are rare in the cancers with approved targeted radionuclide therapies, there is no a priori reason to assume that such treatments would not be effective against brain metastases if the targets are expressed and not shielded by the blood brain barrier. Here, we discuss the current state of the art and opportunities of targeted radionuclide therapies for patients with brain and leptomeningeal metastases.Keywords: brain; leptomeningeal; radioligand; radiopharmaceutical; target; theranostics.
001032446 536__ $$0G:(DE-HGF)POF4-5252$$a5252 - Brain Dysfunction and Plasticity (POF4-525)$$cPOF4-525$$fPOF IV$$x0
001032446 588__ $$aDataset connected to CrossRef, Journals: juser.fz-juelich.de
001032446 7001_ $$0P:(DE-HGF)0$$aAlbert, Nathalie L$$b1
001032446 7001_ $$0P:(DE-HGF)0$$aHüllner, Martin$$b2
001032446 7001_ $$0P:(DE-HGF)0$$aFranceschi, Enrico$$b3
001032446 7001_ $$0P:(DE-Juel1)143792$$aGalldiks, Norbert$$b4
001032446 7001_ $$00000-0002-1254-5310$$aKarschnia, Philipp$$b5
001032446 7001_ $$0P:(DE-HGF)0$$aMinniti, Giuseppe$$b6
001032446 7001_ $$0P:(DE-HGF)0$$aWeiss, Tobias$$b7
001032446 7001_ $$00000-0003-3541-2315$$aPreusser, Matthias$$b8
001032446 7001_ $$0P:(DE-HGF)0$$aEllingson, Benjamin M$$b9
001032446 7001_ $$00000-0002-1748-174X$$aWeller, Michael$$b10
001032446 773__ $$0PERI:(DE-600)2094060-9$$a10.1093/neuonc/noae192$$gp. noae192$$nSupplement_9$$pnoae192$$tNeuro-Oncology$$v26$$x1522-8517$$y2024
001032446 8564_ $$uhttps://juser.fz-juelich.de/record/1032446/files/post-print.pdf$$yRestricted
001032446 909CO $$ooai:juser.fz-juelich.de:1032446$$pVDB
001032446 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)143792$$aForschungszentrum Jülich$$b4$$kFZJ
001032446 9131_ $$0G:(DE-HGF)POF4-525$$1G:(DE-HGF)POF4-520$$2G:(DE-HGF)POF4-500$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$9G:(DE-HGF)POF4-5252$$aDE-HGF$$bKey Technologies$$lNatural, Artificial and Cognitive Information Processing$$vDecoding Brain Organization and Dysfunction$$x0
001032446 9141_ $$y2024
001032446 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-24
001032446 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-24
001032446 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2024-12-11$$wger
001032446 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNEURO-ONCOLOGY : 2022$$d2024-12-11
001032446 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-11
001032446 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-11
001032446 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-11
001032446 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-11
001032446 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-11
001032446 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-11
001032446 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-11
001032446 915__ $$0StatID:(DE-HGF)9915$$2StatID$$aIF >= 15$$bNEURO-ONCOLOGY : 2022$$d2024-12-11
001032446 920__ $$lyes
001032446 9201_ $$0I:(DE-Juel1)INM-3-20090406$$kINM-3$$lKognitive Neurowissenschaften$$x0
001032446 980__ $$ajournal
001032446 980__ $$aVDB
001032446 980__ $$aI:(DE-Juel1)INM-3-20090406
001032446 980__ $$aUNRESTRICTED